JP2013512263A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512263A5
JP2013512263A5 JP2012541335A JP2012541335A JP2013512263A5 JP 2013512263 A5 JP2013512263 A5 JP 2013512263A5 JP 2012541335 A JP2012541335 A JP 2012541335A JP 2012541335 A JP2012541335 A JP 2012541335A JP 2013512263 A5 JP2013512263 A5 JP 2013512263A5
Authority
JP
Japan
Prior art keywords
mitotic checkpoint
schmidt
compounds
present
pharmacological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012541335A
Other languages
English (en)
Japanese (ja)
Other versions
JP5805652B2 (ja
JP2013512263A (ja
Filing date
Publication date
Priority claimed from EP09075527A external-priority patent/EP2343294A1/en
Application filed filed Critical
Publication of JP2013512263A publication Critical patent/JP2013512263A/ja
Publication of JP2013512263A5 publication Critical patent/JP2013512263A5/ja
Application granted granted Critical
Publication of JP5805652B2 publication Critical patent/JP5805652B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012541335A 2009-11-30 2010-11-17 置換トリアゾロピリジン Expired - Fee Related JP5805652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075527.3 2009-11-30
EP09075527A EP2343294A1 (en) 2009-11-30 2009-11-30 Substituted triazolopyridines
PCT/EP2010/006993 WO2011063907A1 (en) 2009-11-30 2010-11-17 Substituted triazolopyridines

Publications (3)

Publication Number Publication Date
JP2013512263A JP2013512263A (ja) 2013-04-11
JP2013512263A5 true JP2013512263A5 (enExample) 2013-12-26
JP5805652B2 JP5805652B2 (ja) 2015-11-04

Family

ID=42026745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541335A Expired - Fee Related JP5805652B2 (ja) 2009-11-30 2010-11-17 置換トリアゾロピリジン

Country Status (7)

Country Link
US (1) US8551980B2 (enExample)
EP (2) EP2343294A1 (enExample)
JP (1) JP5805652B2 (enExample)
CN (1) CN102858768B (enExample)
CA (1) CA2781914A1 (enExample)
ES (1) ES2439776T3 (enExample)
WO (1) WO2011063907A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN103429592A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
JP2014503521A (ja) 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
WO2012080230A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080234A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
JP5964853B2 (ja) 2010-12-17 2016-08-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、6−チオ置換イミダゾピラジン類
ES2571741T3 (es) 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
JP5951750B2 (ja) 2011-04-06 2016-07-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリジン類およびその中間体
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CA2914521A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN114592061A (zh) 2015-04-17 2022-06-07 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH0690447B2 (ja) 1986-09-12 1994-11-14 コニカ株式会社 ハロゲン化銀写真感光材料
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
WO2003000659A1 (en) 2001-06-26 2003-01-03 Nissan Chemical Industries, Ltd. Heterocycloiminophenyl compounds and fungicides and insecticides for agricultural and horticultural use
AU2003268494A1 (en) 2002-09-11 2004-04-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
US20070149553A1 (en) * 2003-12-19 2007-06-28 Arrington Kenneth L Mitotic kinesin inhibitors
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
ATE533497T1 (de) 2005-12-27 2011-12-15 Genentech Inc Verfahren zur verwendung von hedgehog-kinase- antagonisten zur behandlung von hedgehog- vermittelten krebs
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
US8883820B2 (en) 2006-08-30 2014-11-11 Cellzome Ltd. Triazole derivatives as kinase inhibitors
WO2008072777A2 (en) 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
CN101801966A (zh) * 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
US20110118238A1 (en) * 2007-08-23 2011-05-19 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2558840T3 (es) 2007-11-27 2016-02-09 Cellzome Limited Aminotriazoles como inhibidores de la PI3K
CA2708686A1 (en) 2007-12-21 2009-07-02 University Health Network Methods of inhibiting tumor growth using ttk antagonists
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
BRPI0922452A2 (pt) 2008-12-19 2015-12-15 Leo Pharma As composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
NZ594508A (en) 2009-02-13 2013-12-20 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
EP2424537B1 (en) 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
US8367830B2 (en) 2009-05-20 2013-02-05 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
NZ600648A (en) 2010-01-15 2014-06-27 Janssen Pharmaceuticals Inc Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application

Similar Documents

Publication Publication Date Title
JP2013512263A5 (enExample)
JP2013512268A5 (enExample)
JP2013503824A5 (enExample)
JP2013512264A5 (enExample)
ES2648876T3 (es) Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo
CN101848895B (zh) 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
Jhaveri et al. HSP90 inhibitors for cancer therapy and overcoming drug resistance
EP3746436A1 (en) Fused ring compounds
DOP2019000022A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2015512943A5 (enExample)
TW202045181A (zh) 細胞週期蛋白依賴性激酶2生物標記物及其用途
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2019501204A5 (enExample)
JP2017511311A5 (enExample)
CN114599361A (zh) Prmt5抑制剂的药物组合物
NZ628407A (en) Treatment of cancer with tor kinase inhibitors
JP2021502386A (ja) Ash1l分解剤及びそれを用いた治療方法
WO2014145214A2 (en) Inhibitors of prmt5 and methods of their use
HRP20171534T4 (hr) Derivati fosfora kao inhibitori kinaza
AU2018212647A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2017036314A5 (enExample)
JP2014508752A5 (enExample)
BR112014027337A2 (pt) composições orgânicas para tratar doenças relacionadas com kras
WO2012065085A4 (en) Methods of treating cancer
PH12014501832A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme